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Echocardiography On the day of sacrifice cardiac function was assessed using both echocardiography and invasive hemodynamic measurements. Echocardiography was performed under inhalation anesthesia using 1% isoflurane/98% oxygen/1% CO 2 . The chest was shaved and animals were placed in the left lateral position.
Thermoregulation was achieved using an auto-regulated heating blanket. A lineararray probe (15L8) connected to a numeric Sequoia 512 ultrasound device (Acuson, Mountain View, CA, U.S.A.) was used. All measurements were made using the American Society of Echocardiography leading edge to leading edge technique.
Hemodynamic measurements For invasive hemodynamic measurements, animals
were anesthetized with a combination of Hyponorm (Janssen Pharmaceuticals, Dublin, Ireland) and midazolam (Roche pharmaceuticals, Dublin, Ireland). Real-time quantitative RT-PCR Briefly, RNA was extracted using a commercially available protocol that included an on-column DNase step (Rneasy, Qiagen, U.K.). A cDNA copy of RNA was made by reverse transcription. Primers for death-associated protein (DAP) kinase-related apoptosis-inducing protein kinase-2 (DRAK2), a proapoptotic member of the DAP kinase family, and Bcl-xL, an anti-apoptotic member of the Bcl-2 family were designed and commercially synthesized (Applied Biosystems, Cheshire, U.K.). Primers for DRAK2 were: sense, 5'-GAA CAC CTG AAT ACT TAG CTC CAG AAA-3', antisense, 5'-ACG CTA TTA TGC CAA TAT TCC ACA TAT-3'. Primers for Bcl-xL were: sense, 5'-AAT GAA CTC TTT CGG GAT GGA G- (Table) . Intra-aortic pressure readings demonstrated a reduction in systolic blood pressure, diastolic blood pressure, mean arterial pressure and heart rate in COX-2 -/-treated with DOX as compared to WT DOX-treated controls (Table) . Treatment with iloprost attenuated these DOX-induced changes in COX-2 -/-mice with an increase in the maximum rate of change of pressure (dP/dt MAX ), systolic blood pressure, diastolic blood pressure and left ventricular end systolic pressure (LVESP) and a decrease in LVEDP.
Cardiomyocyte apoptosis Cardiac tissue (n=5 animals per group) was assessed for the presence of cardiac cell apoptosis using the TUNEL assay. Over 100,000
cardiomyocytes per group were viewed. At baseline there was no difference in apoptosis between WT and COX-2 -/-
. While DOX induced a three-fold increase in cardiac cell apoptosis in WT animals (0.007±0.001 WT baseline vs. 0.023±0.001%
WT/DOX, P = 0.08), it induced an eight-fold increase in apoptosis in COX-2 -/-mice (Fig 2) .
Quantitative real-time PCR analysis
Quantitative analysis of mRNA demonstrated altered expression of two genes that regulate apoptosis. There was an increase in the expression of the pro-apoptotic gene DRAK2 in COX-2 -/-animals treated with DOX ( Fig 3A) ; this DOX-induced increase in DRAK2 was attenuated by iloprost. In contrast, iloprost increased the expression of the anti-apoptotic gene Bcl-xL in DOXtreated COX-2 -/- (Fig 3B) . We also examined the expression of Bax, HSP-70 and hemeoxygenase-1, these was unaltered by DOX or the combination of DOX and iloprost (data not shown).
H-00863-2005.R1 DISCUSSION
We have previously demonstrated a protective role for COX-2 against DOXinduced cardiac injury using pharmacological inhibitors; an approach that can be confounded by the non-specific effects of the drugs (10) early mortality in affected animals. The animals used in our study were generated using a different backcross (DBA-1) and at the time of study were on average 3 months old, the average age of death for animals in the study by Dinchuk et al, suggesting either natural selection or a different phenotype. Also, normal baseline levels of fibrosis have also been reported in other tissues in COX-2 -/-mice (3, 14) .
Mice with disruption of COX-2 developed less cardiac fibrosis than WT mice after treatment with DOX despite having less apoptosis. Doxorubicin-induced cardiomyocyte apoptosis is an acute process with an early peak and a rapid decline Our work has some limitations. This was an acute study, and the mechanisms involved and the protection afforded by COX-2 against cardiac injury may not completely mirror those seen in the chronic form of DOX-induced dysfunction (7).
The prostacyclin analog used was not selective for the IP receptor with partial agonist 
